- Home
- ATOS vs CGO Comparison
ATOS vs CGO Comparison
Compare ATOS & CGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- CGO
- Stock Information
- Founded
- ATOS 2009
- CGO 2004
- Country
- ATOS United States
- CGO United States
- Employees
- ATOS N/A
- CGO N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- CGO Investment Managers
- Sector
- ATOS Health Care
- CGO Finance
- Exchange
- ATOS Nasdaq
- CGO Nasdaq
- Market Cap
- ATOS 140.9M
- CGO 114.2M
- IPO Year
- ATOS 2012
- CGO N/A
- Fundamental
- Price
- ATOS $0.96
- CGO $11.66
- Analyst Decision
- ATOS Strong Buy
- CGO
- Analyst Count
- ATOS 3
- CGO 0
- Target Price
- ATOS $7.00
- CGO N/A
- AVG Volume (30 Days)
- ATOS 952.6K
- CGO 34.7K
- Earning Date
- ATOS 11-12-2024
- CGO 01-01-0001
- Dividend Yield
- ATOS N/A
- CGO 9.25%
- EPS Growth
- ATOS N/A
- CGO N/A
- EPS
- ATOS N/A
- CGO N/A
- Revenue
- ATOS N/A
- CGO N/A
- Revenue This Year
- ATOS N/A
- CGO N/A
- Revenue Next Year
- ATOS N/A
- CGO N/A
- P/E Ratio
- ATOS N/A
- CGO N/A
- Revenue Growth
- ATOS N/A
- CGO N/A
- 52 Week Low
- ATOS $0.73
- CGO $7.90
- 52 Week High
- ATOS $2.31
- CGO $10.93
- Technical
- Relative Strength Index (RSI)
- ATOS 24.57
- CGO 40.91
- Support Level
- ATOS $1.17
- CGO $11.52
- Resistance Level
- ATOS $1.30
- CGO $11.84
- Average True Range (ATR)
- ATOS 0.08
- CGO 0.19
- MACD
- ATOS -0.02
- CGO -0.03
- Stochastic Oscillator
- ATOS 1.09
- CGO 22.13
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in global equities, convertible securities, and high-yield corporate bonds.